Cosmetics, dermocosmetics and cosmeceuticals in aesthetic medicine: what we have never asked, and why it matters. A clinical perspective
Keywords:
dermocosmetics cosmeceuticals, aesthetic medicine, skin barrier, formulation science, post-procedure careAbstract
Introduction: Dermocosmetics are widely used in aesthetic and dermatologic practices; however, they remain one of the most conceptually misunderstood tools available to clinicians. Terms such as “cosmetic,” “dermocosmetic,” and “cosmeceutical” are frequently employed as if they reflected distinct regulatory or scientific categories, whereas, in practice, they represent cultural, methodological, and clinical gradients rather than legal definitions.
Objectives: This perspective aims to clarify these conceptual boundaries and examine the scientific elements that distinguish dermocosmetics from standard cosmetics, without conferring upon them a therapeutic role.
Methods: By integrating regulatory context, formulation science, methodological rigor, and clinical relevance, this paper provides an evidence-informed framework for evaluating dermocosmetics in clinical practice.
Results: This framework highlights the differences between dermocosmetics and standard cosmetics, offering clinicians a structured approach to interpret their use beyond marketing terminology.
Conclusions: The goal is not to elevate dermocosmetics as a “superior” product class, but to provide clinicians with the knowledge needed to guide patients responsibly in an area where marketing vocabulary often obscures scientific meaning.
References
1. Dréno B, Araviiskaia E, Berardesca E, et al. The science of dermocosmetics and its role in dermatology. J Eur Acad Dermatol Venereol. 2014;28(11):1401-1409
2. Surber C, Smith EW. The mystical effects of dermatological vehicles. Dermatology. 2005;210(2):157-168.
3. European Commission. Technical document on cosmetic claims. Agreed by the Sub-Working Group on Claims (version of 3 July 2013). Brussels; 2013.
4. Newburger AE. Cosmeceuticals: myths and misconceptions. Clin Dermatol. 2009;27(5):446-452.
5. Draelos ZD. Cosmeceuticals: What's Real, What's Not. Dermatol Clin. 2019;37(1):107-115.
6. Madnani N, Khan K. Expert opinion on pre and post procedure care in aesthetic dermatology. Int J Res Med Sci. 2022;10(4):991-1000.
7. Regulation (EC) No 1223/2009 of the European Parliament and of the Council of 30 November 2009 on cosmetic products. Off J Eur Union. 2009;L342:59-209.
8. Kligman A. The question of cosmeceuticals. Dermatol Clin. 2000;18(4):609-616.
9. Ribet V, Gurdak M, Ferret PJ, et al. Stepwise approach of development of dermo-cosmetic products in healthy and atopic dermatitis paediatric population: safety evaluation, clinical development and postmarket surveillance. J Eur Acad Dermatol Venereol. 2019; 33(12):2319-2326.
10. Ribet V, Albinet Claudin L, Brinio E, et al. Surveillance of dermo-cosmetic products: a global cosmetovigilance system to optimise product development and consumer safety. Eur J Dermatol. 2021; 31(4):463-469.
11. Wollenberg A, et al Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. J Eur Acad Dermatol Venereol. 2018 May;32(5):657-682.
12. Mias C, Chansard N, Maitre M, et al. Myrtus communis and Celastrol enriched plant cell culture extracts control together the pivotal role of Cutibacterium acnes and inflammatory pathways in acne. J Eur Acad Dermatol Venereol. 2023;37(Suppl 2):12-19.
13. Saurat JH, Reygagne P, Josse G, et al. Long-Term Use of Silybum marianum fruit extract Contributes to Homeostasis in Acne-Prone Skin—A 12-Month Follow-Up International “Real Life” Cohort Study. J Pers Med. 2023;13(1):96.
14. Bageorgou F, Li L, Beausillon C, et al. Tolerability and effectiveness of a dermocosmetic product containing Silybum marianum fruit extract in adolescents and young adults with acne-prone skin: An international, phase IV, longitudinal study. J Cosmet Dermatol. 2023;22(8):2259-2267.
15. Vendrely V, Mayor-Ibarguren A, Stennevin A, Ortiz-Brugués A. An Emollient PLUS Balm Is Useful for the Management of Xerosis in Patients Treated for Cancer: A Real-World, Prospective, Observational, Multicenter Study. Dermatol Ther (Heidelb). 2022;12(3):683–699.
16. Shi Y, Lain E, Frasson N, et al. The Real-World Effectiveness and Tolerability of a Soothing Cream Containing the Postbiotic Aquaphilus dolomiae Extract-G2 for Skin Healing. Dermatol Ther (Heidelb). 2024;14(3):697-712.
17. Dréno B, Araviiskaia E, Berardesca E, et al. Microbiome in healthy skin, update for dermatologists. J Eur Acad Dermatol Venereol. 2016;30(12):2038-2047.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Cristina Georgescu, Emanuele Bartoletti
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Transfer of Copyright and Permission to Reproduce Parts of Published Papers.
Authors retain the copyright for their published work. No formal permission will be required to reproduce parts (tables or illustrations) of published papers, provided the source is quoted appropriately and reproduction has no commercial intent. Reproductions with commercial intent will require written permission and payment of royalties.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
